STC314
Based on 1 Customer Validation
STC314 is a histone-neutralizing agent. STC314 inhibits histone-mediated cytotoxicity, blocks histone-induced erythrocyte aggregation, reduces fragility, restores deformability and inhibits histone-induced aggregation and degranulation in human erythrocytes. STC314 reduces histone-mediated tissue damage, thrombocytopenia, anemia, and cell death, and improves survival in preclinical models. STC314 can be used for the research of sepsis, ischemia-reperfusion injury, and deep-vein thrombosis.
For research use only. We do not sell to patients.
- Purity: 98.0%
- CAS No.: 401513-39-1
- Formula: C13H17Na7O32S7
- Molecular Weight:1070.64
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
STC314 (Compound mCBS) (20-100 μg/mL; 1 h) potently inhibits histone-mediated cytotoxicity in HMEC-1 cells[1].
STC314 (12.5-400 μg/mL; 15 min-1 h) blocks histone-induced erythrocyte aggregation, reduces fragility, restores deformability and inhibits histone-induced aggregation and degranulation in human erythrocytes[1].
STC314 (mCBS) (0.9-500 μg/mL) stabilizes human NETs and does not displace histones from chicken RBC chromatin[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:human microvascular endothelial cell-1 (HMEC-1)
-
Concentration:0-100 μg/mL
-
Incubation Time:1 h
-
Result:Inhibited histone-mediated HMEC-1 cytotoxicity.
STC314 (100 mg/kg; i.p.; single dose 2 hours post-histone injection) significantly reduces ongoing histone-induced multi-organ damage and cell death in male C57BL/6 mice when administered 2 hours after histone exposure[1].
STC314 (50 mg/kg; i.p.; four total doses: 5 minutes pre-clamp, 5 minutes post-clamp removal, 24 hours post-surgery, 48 hours post-surgery) significantly improves skin flap viability in male Wistar rats following ischemia-reperfusion injury[1].
STC314 (50 mg/kg; i.v.; single dose 5 minutes post-histone injection) almost completely prevents histone-induced deep vein thrombosis in male C57BL/6 mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c (female, 5-6 weeks of age, histone-induced sepsis-like syndrome model)[1]
-
Dosage:6.25 mg/kg; 25 mg/kg; 100 mg/kg
-
Administration:i.p.; single dose 10 minutes pre-histone injection
-
Result:Prevented histone-induced thrombocytopenia (maintained circulating platelet counts near control levels).
Prevented histone-induced anemia (maintained circulating red blood cell counts near control levels and reduced splenic hemoglobin accumulation to near control levels).
Reduced circulating alanine aminotransferase, lactate dehydrogenase, and creatinine levels in a dose-dependent manner, with 100 mg/kg providing the greatest reduction.
-
Animal Model:Wistar (male, 8-12 weeks old, 250-350 g, CLP-induced sepsis model)[2]
-
Dosage:50 mg/kg
-
Administration:i.p.; four total doses: 5 minutes pre-CLP, 5, 10, 15 hours post-CLP
-
Result:Resulted in 100% survival of rats at 20 hours post-CLP (compared to reduced survival in untreated controls).
Normalized circulating alanine aminotransferase and creatinine levels, preventing CLP-induced liver and kidney damage.
-
Animal Model:Wistar (male, 8-12 weeks old, 250-350 g, skin flap ischemia-reperfusion injury model)[1]
-
Dosage:50 mg/kg
-
Administration:i.p.; four total doses: 5 minutes pre-clamp, 5 minutes post-clamp removal, 24 hours post-surgery, 48 hours post-surgery
-
Result:Significantly increased the viable area of the ischemic skin flap, with consistent improvement observed across treated rats.
-
Animal Model:C57BL/6 (male, 8 weeks of age, histone-induced deep vein thrombosis model)[1]
-
Dosage:50 mg/kg
-
Administration:i.v.; single dose 5 minutes post-histone injection
-
Result:Almost completely inhibited histone-induced DVT, with thrombus weights reduced to near sham-operated control levels.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 401513-39-1
-
Appearance Solid
-
Molecular Weight 1070.64
-
Formula C13H17Na7O32S7
-
Color White to off-white
-
SMILES
O=[S](O[C@H]([C@H]1O[S](=O)(O[Na])=O)[C@@H]([C@H](O[C@H]1OC)CO[S](=O)(O[Na])=O)O[C@H](O[C@@H]2CO[S](=O)(O[Na])=O)[C@@H]([C@H]([C@@H]2O[S](=O)(O[Na])=O)O[S](=O)(O[Na])=O)O[S](=O)(O[Na])=O)(O[Na])=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
H2O : 8.33 mg/mL (7.78 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (293 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 0.9340 mL | 4.6701 mL | 9.3402 mL | 23.3505 mL |
| 5 mM | 0.1868 mL | 0.9340 mL | 1.8680 mL | 4.6701 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
STC314 Related Classifications
HY-145996 Related Classifications
Powered by Bioz